Skip to main content

Branded

  • FDA updates ongoing safety review of Actos

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.

  • FDA approves Nulojix

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for preventing organ rejection in kidney transplant patients, the agency said Wednesday.

    The FDA approved Bristol-Myers Squibb’s Nulojix (belatacept), for preventing acute rejection in adult patients. The drug is approved for use with other immune system-suppressing drugs, specifically Novartis’ Simulect (basiliximab), Genentech’s CellCept (mycophenolate mofetil) and corticosteroids.

  • Axium adds new drugs to HepVisions therapy management program

    LAKE MARY, Fla. — Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.

    Axium announced the addition of Merck ’s Victrelis (boceprevir) and Vertex Pharmaceuticals’ Incivek (telaprevir) to the program, through which it provides comprehensive compliance support, patient education, side effect management, clinical interventions and communication with the patient and physician.

  • Sanofi, Audion enter research collaboration for hearing loss treatments

    PARIS — French drug maker Sanofi has entered a collaboration with Audion Therapeutics to develop treatments for hearing loss.

    Sanofi announced the collaboration Thursday, which will utilize technology that Audion co-founder Albert Edge developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory. Sanofi will have the option of licensing technology rights from Audion related to research conducted under the collaboration.

  • Tradjenta now available in U.S. pharmacies

    INDIANAPOLIS — A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday.

    Lilly and BI announced the availability of Tradjenta (linagliptin) in chain and independent pharmacies around the country.

  • Lilly for Better Health provides patients with ways to improve well-being

    INDIANAPOLIS — Drug maker Eli Lilly has created a multichannel platform to inform and educate patients about healthy eating, physical activity and stress management.

    The program, Lilly for Better Health, is designed to help users live healthier, more active lives, and Lilly said it was designed to reach patients where they like to receive health information. The program includes a website, LillyForBetterHealth.com.

  • Cypress gets OK for cough-cold medications Zutripro, Rezira

    MADISON, Miss. — The Food and Drug Administration has approved two cough-cold medications made by Cypress Pharmaceutical, the company said Monday.

    Cypress announced the approval of Zutripro (hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride) and Rezira (hydrocodone bitartrate and pseudoephedrine). Both drugs are oral solutions and, because they contain the opioid hydrocodone, are classified as schedule III controlled substances by the Drug Enforcement Administration. Cypress subsidiary Hawthorn Pharmaceuticals will market the drugs.

  • FDA OKs infant-specific dose of Creon

    ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new dosage of a drug made by Abbott for treating cystic fibrosis in infants, the drug maker said Tuesday.

    Abbott announced the approval of an infant-specific dose of Creon (pancrelipase) delayed-released capsules to treat exocrine pancreatic insufficiency due to cystic fibrosis.

X
This ad will auto-close in 10 seconds